Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome

Karen W.L. Yee, Jorge Cortes, Alessandra Ferrajoli, Guillermo Garcia-Manero, Srdan Verstovsek, William Wierda, Deborah Thomas, Stefan Faderl, Ivan King, Susan M. O'Brien, Sima Jeha, Michael Andreeff, Ann Cahill, Mario Sznol, Francis J. Giles

Research output: Contribution to journalArticlepeer-review

51 Scopus citations


Triapine®, an iron chelator and a potent inhibitor of ribonucleotide reductase, has significant anti-leukemia activity. A phase I study of Triapine in combination with ara-C was conducted in 32 patients with refractory acute leukemia and high-risk MDS. Triapine (105 mg/m2/day 6-h infusion) was followed immediately by ara-C [100 (n = 4), 200 (n = 6), 400 (n = 7), or 800 (n = 8) mg/m2/day] as an 18-h infusion for 5 consecutive days. Dose-limiting toxicities (DLTs) were observed at the 800 mg/m2 ara-C dose level (one patient each with grade 4 mucositis; grade 4 neutropenic colitis, sepsis; grade 4 neuropathy; and grade 4 hyperbilirubinemia). Therefore, the study was amended to include an ara-C dose level of 600 mg/m2/day, no DLTs occurred in seven patients treated at this dose level. Mean Triapine Cmax and AUC were 1.13 μg/mL and 251.5 min μg/mL. Of 31 evaluable patients, 4 (13%) (3 AML, 1 Ph + ALL) achieved a CR (1 at a dose of 800 mg/m2; 2 at 600 mg/m2; 1 at 200 mg/m2). The recommended phase II regimen is Triapine 105 mg/m2/day followed by ara-C 600 mg/m2/day for 5 consecutive days every 3-6 weeks.

Original languageEnglish (US)
Pages (from-to)813-822
Number of pages10
JournalLeukemia Research
Issue number7
StatePublished - Jul 2006
Externally publishedYes


  • Acute lymphocytic leukemia
  • Acute myeloid leukemia
  • Cytarabine
  • Myelodysplastic syndrome
  • Ribonucleotide reductase
  • Triapine

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome'. Together they form a unique fingerprint.

Cite this